Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group

This publication has 12 references indexed in Scilit:

• KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
  Health Technology Assessment, 2014
• Reflections on Market Access for Personalized Medicine: Recommendations for Europe
  Value in Health, 2013
• Growth of Molecular Diagnostics and Genetic Testing in the USA, 2008–2011: Analysis and Implications
  Personalized Medicine, 2013
• Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
  Value in Health, 2013
• Beyond Diagnostic Accuracy: The Clinical Utility of Diagnostic Tests
  Clinical Chemistry, 2012
• Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
  Value in Health, 2012
• Payers and the Assessment of Clinical Utility for Companion Diagnostics
  Clinical Pharmacology & Therapeutics, 2010
• Health Technology Assessment
  IEEE Engineering in Medicine and Biology Magazine, 2010
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
  Genetics in Medicine, 2009
• Evaluation of diagnostic tests when there is no gold standard. A review of methods
  Health Technology Assessment, 2007